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Background: The goal of treatment of functional constipation (FC) is to restore a regular
defecation pattern and to prevent relapses. Aim: To assess long-term outcomes in child-
ren with FC. Methods: This was a follow-up study of children previously enrolled in
2 independent randomized controlled trials. In the ﬁrst trial, children randomly received
glucomannan (GNN) or placebo for 4 weeks. In the second study, children received
a fermented dairy product with Biﬁdobacterium lactis I-2494 (B. lactis) or placebo for
3 weeks. Follow-up data were collected using a standardized questionnaire. The primary
outcome measure was treatment success (3 spontaneous bowel movements with no
episodes of soiling during the last week, abdominal pain, or need for laxatives). The
secondary outcomes were FC according to the Rome III criteria and the need for laxative
therapy. Results: In the GNN study, follow-up data at 24 months were obtained from 63
of 72 (87.5%) of children. Treatment success was reported in 36/63 (57%), FC in 17/63
(27%), and the need for laxatives in 13/63 (21%). There were no differences in outcomes
between groups. In the B. lactis study, follow-up data at 36 months were obtained from
57 of 82 (70%) of children. Treatment success was reported in 26/57 (46%), FC in 21/57
(37%), and the need for laxatives in 15/57 (26%). There were no differences in outcomes
between groups. Conclusion: A substantial portion of children remained symptomatic
after 2–3 years of follow-up indicating a need for regular evaluation of children with FC.
© 2013 Polish Pediatric Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Functional constipation is a common gastrointestinal prob-
lem in children. The estimated worldwide prevalence varies
from 1% to 30% [1, 2]. Currently, the diagnosis of functional* Corresponding author at: Klinika Pediatrii, Warszawski Uniwersytet 
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http://dx.doi.org/10.1016/j.pepo.2013.02.005constipation is based on the Rome III criteria and includes
two or more of the following: 2 defecations in the toilet
per week; at least one episode of fecal incontinence per
week; history of retentive posturing or excessive volitional
stool retention; history of painful or hard bowel movements;
presence of a large fecal mass in the rectum; and a historyMedyczny, ul. Działdowska 1, 01-184 Warszawa, Poland.
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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The criteria are fulﬁlled when their deﬁning symptoms
appear at least once per week for at least 2 months prior to
diagnosis [3]. Evidence-based guidelines from the North
American Society of Pediatric Gastroenterology, Hepatology
and Nutrition (NASPGHAN) [4], as well as the National
Institute for Health and Clinical Excellence (NICE) guidelines
[5], consistently recommend disimpaction, if present, follo-
wed by a maintenance therapy. Available therapeutic mea-
sures include toilet training and the use of oral osmotic
laxatives (e.g., lactulose, polyethylene glycol), stimulant
laxatives (e.g., bisacodyl), or mineral oil [4–6]. However, none
of these measures offers long-lasting effects, hence, interest
in alternative therapies.
Previously, we evaluated the effect of gut microbiota
modiﬁcation with prebiotics or probiotics in children with
functional constipation in 2 randomized controlled trials
[7, 8]. The rationale for the use of prebiotics/probiotics in
the treatment of functional constipation was based on data
demonstrating differences in the intestinal microbiota bet-
ween healthy individuals and patients with chronic consti-
pation [9, 10]. In these studies, the rate of treatment success
ranged from 57% [8] to 67% [9], but there was no difference
between the groups in any of the studies.
Constipation unfavorably inﬂuences the quality of life of
affected children [11, 12]. While the goal of treatment of
functional constipation is to restore a regular defecation
pattern and to prevent relapses, the persistence of symp-
toms of constipation was reported in 30–52% of children
followed up for at least 5 years [13, 14]. This indicates that
functional constipation is not a transient, mild disorder.
Data from Poland are limited. The aim of the current study
was to assess long-term outcomes in children with functio-
nal constipation who had participated in those 2 previous
trials [8, 9].
Methods
The current trial was a follow-up study of children who had
participated in 2 previously published, randomized control-
led trials carried out at our center. The designs of these
studies have been described elsewhere [8, 9]. Brieﬂy, in the
ﬁrst trial (n = 80) [8], children aged 3–16 years with functional
constipation according to the Rome III criteria were ran-
domly assigned to receive glucomannan (GNN), 2.52 g/d, or
a comparable placebo for 4 weeks. GNN was as effective asTable I – Baseline characteristics
Tabela I – Charakterystyka badanych populacji
GNN 
N 40 
Male/female 18/22 
Age, years (mean  SD) 6.1  3.3 
Duration of constipation in years (mean  SD) 2.7  3.1 
Stool frequency per week (mean  SD) 1.73  0.55 
B. lactis – Biﬁdobacterium lactis I-2494; GNN – glucomannan.placebo in achieving therapeutic success in constipated
children [8]. In the second, multicenter, 2-nation (The
Netherlands and Poland) trial (n = 159) [9], children aged
3–16 years with functional constipation according to the
Rome III criteria were randomly allocated to receive
a fermented dairy product with Biﬁdobacterium lactis I-2494
(B. lactis) twice daily for 3 weeks or a comparable placebo.
The effectiveness of the experimental treatment was com-
parable to that of the placebo [9].
Follow-up data were collected using a standardized ques-
tionnaire at 24 months after completion of the GNN study
and at 36 months after completion of the B. lactis study.
Participants were contacted by phone or regular mail. The
questions asked related to the frequency, size, and consis-
tency of stools defecated into the toilet, the presence of
abdominal pain, and the need for laxative therapy. The
primary outcome measure was treatment success, deﬁned
as 3 spontaneous bowel movements with no episodes of
soiling during the last week, no abdominal pain, and no
need for laxative treatment. The secondary outcomes were
functional constipation according to the Rome III criteria
and the need for laxative treatment.
Statistical analysis
The computer software Stats Direct [version 2.7.9.(2012-07-
09)] was used to calculate the relative risk (RR) and mean
difference (MD), both with a 95% CI. The difference between
study groups was considered signiﬁcant when the p value
was <0.05, when the 95% CI for RR did not include 1.0, or
when the 95% CI for MD did not include 0. All statistical
tests were two tailed and performed at the 5% level of
signiﬁcance.
Results
The baseline characteristics of the 2 included populations
[8, 9] are summarized in Table I. The primary and secondary
outcomes are summarized in Table II.
In the GNN study, follow-up data at 24 months were
obtained from 63 of 72 (87.5%) of the children. Overall,
treatment success was reported in 36 of 63 (57%) of the
children, and there was no difference in treatment success
rates between the GNN and placebo groups (RR 1.08, 95% CI
0.70 to 1.66). Functional constipation was reported in 17 ofStudy #1 Study #2
Placebo B. lactis Placebo
40 42 40
16/24 23/19 18/22
5.9  2.5 6.5  3.6 6.2  3.1
2.6  2.9 2.9  2.2 2.7  2.7
1.7  0.5 1.7  0.5 1.7  0.1
Table II – Primary and secondary outcomes
Tabela II – Pierwotne i wtórne punkty końcowe
Study #1 (Follow-up at 24 months) Study #2 (Follow-up at 36 months)
Overall GNN Placebo RR (95% CI) Overall B. lactis Placebo RR (95% CI)
Treatment success 36/63 (57%) 19/32 (59%) 17/31 (55%) 1.08 (0.70–1.66) 26/57 (46%) 13/29 (45%) 13/28 (46%) 0.97 (0.55–1.70)
Functional constipation
(Rome III criteria)
17/63 (27%) 8/32 (25%) 9/31 (29%) 0.86 (0.38–1.94) 21/57 (37%) 11/29 (38%) 10/28 (36%) 1.06 (0.54–2.10)
Need for laxatives 13/63 (21%) 6/32 (19%) 7/31 (23%) 0.83 (0.31–2.20) 15/57 (26%) 7/29 (24%) 8/28 (29%) 0.84 (0.35–2.02)
CI – conﬁdence interval; RR – relative risk.
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groups (RR 0.86, 95% CI 0.38 to 1.94). The need for laxatives
was reported in 13 of 63 (21%) of the children; the rate was
similar in both groups (RR 0.83, 95% CI 0.31 to 2.20). The
mean age of children with constipation was higher than
that of children with treatment success, although the
difference was of borderline statistical signiﬁcance (9.7
 3.19 vs. 7.83  3.4 years; MD 1.87, 95% CI 0.01 to 3.75).
In the B. lactis study, only a subset of 76 children enrolled
in Poland was invited to participate in the present follow-
up. Follow-up data at 36 months were obtained from 57 of
82 (70%) of the children (Table II). Treatment success was
achieved in 26 of 57 (46%) of the children, and the rate did
not differ between the B. lactis and placebo groups (RR 0.97,
95% CI 0.55 to 1.70). Functional constipation was diagnosed
in 21 of 57 (37%) of the children. The rate of functional
constipation was similar in the B. lactis and the placebo
groups (RR 1.06, 95% CI 0.54 to 2.10). The need for laxatives
was reported in 15 of 57 (26%) of the children, and the rate
was similar in both groups (RR 0.84, 95% CI 0.35 to 2.02). The
mean age of children with constipation was signiﬁcantly
higher than that of children with treatment success (11.38
 3.44 vs. 8.8  2.71 years; MD 2.58, 95% CI 0.78 to 4.38).
Discussion
Principal ﬁndings
This follow-up study of children previously enrolled in
2 independent, randomized controlled trials [8, 9] showed
that a substantial portion of the children remained sympto-
matic after 2–3 years of follow-up. Approximately one
quarter of the children fulﬁlled the strict Rome III criteria
for functional constipation or needed laxatives. Children
with constipation were older than children with treatment
success.
Strengths and limitations
The study population is one of the major strengths of our
study. We followed up a homogeneous population in which
the initial diagnosis of functional constipation was made
based on standardized Rome III criteria [3]. While different
interventions were used in the original studies, both were
similar in nature, i.e., focused on modiﬁcation of gut
microbiota. Hence, our decision to present the results of
both cohorts in a single report. As initially no differenceswere found between the experimental and the control
groups, our main focus was on long-term outcomes and not
on the differences between groups. The response rate to the
invitation to this follow-up study was high. This was
particularly true for the GNN study that was carried out
exclusively at our center. In regard to the B. lactis study, the
response rate to this follow-up study was also high; how-
ever, we only invited children living in Poland to participate.
Thus, the results from the B. lactis study should be inter-
preted with caution. Still, the ﬁndings compare well with
those of the GNN study, which reduces the risk of attrition
bias.
Comparison with previous ﬁndings
In general, our results are consistent with previously publi-
shed observations. One of the ﬁrst, long-term, follow-up
observations was reported in 1993 by Loening-Baucke [15]
who evaluated long-term outcomes in 90 of 174 (52%)
children (mean age: 6.9  2.7 years) after an initial diagnosis
of constipation. Treatment success, deﬁned as no soiling
with 3 bowel movements per week while not receiving
treatment, was observed in 57 of 90 (63%) of the children.
The recovery rate was signiﬁcantly higher in children 2
years of age than in children between 2 and 4 years of age.
Symptoms of chronic constipation persisted in one third of
patients, 3–12 years after initial evaluation and treatment.
Staiano et al. [16] followed up 62 children (mean age: 5.2
 2.8 years) with chronic idiopathic constipation for a period
of 5 years. Each child received the same initial treatment
over a 12-week period and was then followed up every
3 months. After 5 years from diagnosis, functional constipa-
tion persisted in 52% of the children [16].
Van Ginkel et al. [17] reported data on 418 constipated
children (median age: 8 years) who were followed up 5 years
(range: 1–8 years) after intensive initial medical and behavio-
ral treatment. The cumulative percentage of children who
were treated successfully during follow-up was 60% at 1 year,
increasing to 80% at 8 years. Successful treatment was more
frequent in children without encopresis and in children with
the onset of bowel problems when older than 4 years of age.
In a non-blinded, randomized study by Loening-Baucke
and Pashankar [15], 79 children (mean age: 8.1  3.0 years)
with chronic constipation and fecal incontinence were
assigned randomly to receive polyethylene glycol (n = 39) or
milk of magnesia (n = 40). After 12 months, the percentages of
children who experienced improvement were similar in both
groups (62% vs. 43%, respectively, p < 0.086). Furthermore,
p e d i a t r i a p o l s k a 8 8 ( 2 0 1 3 ) 2 1 9 – 2 2 322233% of the polyethylene glycol-treated children and 23% of
the milk of magnesia-treated children had recovered
( p = 0.283).
Finally, van den Berg et al. [16] attempted to describe the
clinical course of severe functional constipation in early
childhood. Forty-seven children (median age: 3.5 months)
who had constipation during their ﬁrst year of life were
observed. Treatment success was deﬁned as a period of at
least 4 weeks with 3 painless bowel movements per week.
Six months after the initial evaluation, 69% of the children
had recovered. After initial success, a relapse occurred in
15% of the children within 3 years. A shorter duration of
symptoms (<3 mo) before referral correlated signiﬁcantly
with a better outcome.
In Poland, one long-term, follow-up study [17] revealed
that 60% of all children (2–16 years) initially recruited for
treatment with Lactobacillus GG as an adjunct to lactulose or
lactulose alone were treated successfully at 24 months.
However, 25% (20/79) of the children continued to use
laxatives during the last 6 months of the study.
Collectively, the available data are consistent with regard
to the rate of recovery and exacerbations of constipation.
However, evidence is insufﬁcient to identify risk factors
associated with poor, long-term, clinical outcomes.
Conclusion
A follow-up of children with functional constipation diagno-
sed according to the Rome III criteria showed that
a substantial number of children continue to have bowel
problems. Identiﬁcation of the predictive factors of an
unsatisfactory course of constipation seems to be the basis
for the development of accurate preventive strategies. These
data conﬁrm that functional constipation is not a mild, self-
limiting entity.
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